Evidence map›Paper›PMID 23633748›Full record

ArticleSleep2013

Mirtazapine provokes periodic leg movements during sleep in young healthy men.

Stephany Fulda, Stefan Kloiber, Tatjana Dose, Susanne Lucae, Florian Holsboer, Ludwig Schaaf, Johannes Hennings

Registry-linked trialOpen access · bronzeAbstract readControlled Clinical Trial
In one paragraph

Article in Sleep, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00878540 (Phase 1 Study of Mirtazapine in Healthy Subjects), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00878540 phase1completednot on this map

Phase 1 Study of Mirtazapine in Healthy Subjects

TypeinterventionalSponsorMax-Planck-Institute of PsychiatryRan2008 to 2010Enrolled12ConditionsHealthyArmsmirtazapine
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020
    Trial
  3. Article
  4. Review
  5. Consensus Guidelines on Rodent Models of Restless Legs Syndrome.Movement disorders : official journal of the Movement Disorder Society · 2021
    Review
  6. Respiratory-Related Leg Movements of Sleep Are Associated With Serotonergic Antidepressants But Not Bupropion.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2018
    Article
  7. Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2017
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Stephany FuldaMax Planck Institute of Psychiatry, Munich, Germany. stephany.fulda@gmail.com
Stefan Kloiber
Tatjana Dose
Susanne Lucae
Florian Holsboer
Ludwig Schaaf
Johannes Hennings
Max Planck Society · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

objectivesRecent evidence suggests that certain antidepressants are associated with an increase of periodic leg movements (PLMS) that may disturb sleep. So far, this has been shown in patients clinically treated for depression and in cross-sectional studies for various substances, but not mirtazapine. It is unclear whether antidepressants induce the new onset of PLMS or only increase preexisting PLMS, and whether this is a general property of the antidepressant or only seen in depressed patients. We report here the effect of mirtazapine on PLMS in young healthy men.

designOpen-labeled clinical trial (NCT00878540) including a 3-week preparatory phase with standardized food, physical activity, and sleep-wake behavior, and a 10-day experimental inpatient phase with an adaptation day, 2 baseline days, and 7 days with mirtazapine.

settingResearch institute.

participantsTwelve healthy young (20-25 years) men.

interventionsSeven days of nightly intake (22:00) of 30 mg mirtazapine. MEASUREMENTS AND

resultsSleep was recorded on 2 drug-free baseline nights, the first 2 drug nights, and the last 2 drug nights. Eight of the 12 subjects showed increased PLMS after the first dose of mirtazapine. Frequency of PLMS was highest on the first drug night and attenuated over the course of the next 6 days. Three subjects reported transient restless legs symptoms.

conclusionsMirtazapine provoked PLMS in 67% of young healthy males. The effect was most pronounced in the first days. The possible role of serotonergic, noradrenergic and histaminergic mechanisms in mirtazapine-induced PLMS is discussed.

Indexed as

AdultAge FactorsAntidepressive Agents, TricyclicBody Mass IndexCohort StudiesDrug Administration ScheduleHealth StatusHumansMaleMianserinMirtazapineNocturnal Myoclonus SyndromeRisk FactorsSex FactorsYoung AdultAntidepressive Agents, TricyclicMianserinMirtazapineMirtazapineperiodic leg movementsrestless legs syndromesleep

Identifiers

PMID23633748
PMCPMC3624820
OpenAlexW795727149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.